Physician profile
Edward Mack Epstein
NPI 1023202447
$440.94
in general payments reported to CMS, 2019-2025
8 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.22 · 2021: $182 · 2023: $49.81 · 2024: $86.51 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218 · Education: $22.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.56 |
| Education | $22.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $161.96 | 2021-2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $103.09 | 2021-2025 | Farxiga |
| Vifor Pharma, INC. | $55.78 | 2023-2024 | Veltassa |
| Novartis Pharmaceuticals Corporation | $33.37 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.08 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $22.09 | 2023 | Rayaldee |
| Recor Medical INC | $20.35 | 2025 | Paradise Ultrasound Renal Denervation System |
| Nxstage Medical, INC. | $19.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.